Ifosfamide |
Ifex |
Article: Ifosfamide
![]() | |
| Ifosfamide | |
| Systematic (IUPAC) name | |
| 3-(2-chloroethyl)-2 -[(2-chloroethyl)amino]tetrahydro -2H-1,3,2-oxazaphosphorine 2-oxide | |
| Identifiers | |
| CAS number | ? |
| ATC code | ?? |
| PubChem | ? |
| DrugBank | ? |
| Chemical data | |
| Formula | C7H15Cl2N2O2P |
| Mol. weight | 261.1 |
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Metabolism | Hepatic |
| Half life | 60-80% in 72 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | intravenously |
Ifosfamide (pronounced eye.fos'.fa.mide) (also marketed as Mitoxana and Ifex) is is a white powder which, when prepared for use in chemotherapy becomes a clear, colorless fluid. The delivery is intravenous, and is given as a treatment for a variety of cancers, including:
- Testicular cancer
- Breast cancer
- Lymphoma (Non-Hodgkin)
- Soft tissue sarcoma
- Osteogenic sarcoma
- Lung cancer
- Cervical cancer
- Ovarian cancer
- Bone cancer
Ifosfamide is often used in conjunction with mesna to avoid internal bleeding in the patient.

Not Signed In - 


